Application of L100Q site mutation of PCBP1 gene in colorectal cancer drug resistance

By identifying the L100Q site mutation of the PCBP1 gene as a target, the prediction and treatment problems of colorectal cancer's resistance to oxaliplatin or 5-FU are solved, significantly improve drug resistance, promote the development of personalized treatment, Important clinical value.

CN118937677AActive Publication Date: 2024-11-12THE SIXTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202410996702.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-24
Publication Date
2024-11-12
Estimated Expiration
2044-07-24

AI Technical Summary

Technical Problem

The prior art has limited the problems of insufficient prediction accuracy, complexity of drug resistance of drug resistance to oxaliplatin or 5-FU in predicting and overcoming colorectal cancer, which Popularization and application of personalized treatment.

Method used

By discovering the L100Q site mutation of the PCBP1 gene as a target, it provides biomarkers for evaluating drug resistance risks, preparing targeted drugs and diagnostic reagents, which are used to guide personalized treatment in patients with colorectal cancer and significantly promote the stemness of tumor cells. and drug resistance.

Benefits of technology

Mutations in the L100Q locus of PCBP1 gene significantly improve the resistance of colorectal cancer to oxaliplatin and 5-FU, providing a potential target for personalized treatment, with broad application prospects and important clinical value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118937677A_ABST
    Figure CN118937677A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicines, and discloses application of L100Q site mutation of a PCBP1 gene in colorectal cancer drug resistance. The invention provides application of PCBP1 gene L100Q site mutation in preparation of a biomarker for evaluating the colorectal cancer drug resistance risk, application of the PCBP1 gene L100Q site mutation as a target point in preparation of a medicine for treating and / or preventing colorectal cancer drug resistance, application of the PCBP1 gene L100Q site mutation as a screening marker of a medicine for resisting colorectal cancer drug resistance and application of the PCBP1 gene L100Q site mutation as a target point in preparation of a diagnostic reagent for tumor drug resistance. The L100Q site mutation of the PCBP1 gene can obviously promote the dryness of colorectal cancer tumor cells and lead the colorectal cancer to be resistant to oxaliplatin and 5-FU, the L100Q site mutation can be used as a potential treatment site for patients with the colorectal cancer resistant to oxaliplatin or 5-FU, and the potential target spot can be used for guiding personalized treatment of CRC patients and has wide application prospects and important clinical value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biomedicine, and in particular to an application of a PCBP1 gene L100Q site mutation in drug resistance of colorectal cancer. Background Art

[0002] Colorectal cancer (CRC) is the third most common solid tumor in the world. Adjuvant chemotherapy is recommended for patients with stage II colon cancer and high-risk factors (poor histological differentiation with normal mismatch repair or stable microsatellite, T4, vascular lymphatic invasion, preoperative intestinal obstruction, intestinal perforation, insufficient or less than 12 lymph nodes detected in the specimen, nerve invasion, positive or undetermined resection margin) and stage III CRC patients. The recommended chemotherapy regimen is the oxaliplatin-based CapeOx or FOLFOX regimen or single-agent 5-FU / LV and capecitabine. The chemotherapy drugs selected for patients with advanced or metastatic CRC are also based on oxaliplatin or 5-FU.

[0003] CRC patients have clinical resistance to oxaliplatin or 5-FU. At present, studies have revealed some mechanisms of oxaliplatin or 5-FU resistance, including changes in DNA repair mechanisms, changes in metabolic pathways in tumor cells, and reduced ability of drugs to bind to cellular DNA. By exploring these mechanisms, new targets and strategies can be provided to overcome oxaliplatin or 5-FU resistance. In recent years, with the in-depth understanding of the molecular mechanisms of tumor resistance, the treatment of CRC has also tended to be individualized. Screening and targeted treatment based on tumor molecular characteristics are becoming a research hotspot for CRC treatment. These studies mainly focus on the following aspects: Immunotherapy has become an important part of CRC treatment. Clinical trials have shown that immunotherapy drugs such as PD-1 and PD-L1 inhibitors may be effective for some oxaliplatin-resistant CRC patients; targeted therapy for specific CRC mutations is also an important direction for personalized treatment. For example, targeted drugs for RAS and BRAF mutations have shown some efficacy in clinical trials; through in-depth studies of the genome and transcriptome of CRC patients, researchers are looking for new biomarkers associated with oxaliplatin or 5-FU resistance in order to better predict patients' response to treatment and develop new treatment strategies. In general, research on personalized treatment of CRC to overcome oxaliplatin or 5-FU resistance is deepening.

[0004] However, despite some progress in personalized treatment of CRC to overcome oxaliplatin or 5-FU resistance, there are still some technical shortcomings and challenges: 1) Insufficient accuracy in predicting treatment effects: Current prediction models and biomarkers have not yet been able to accurately predict patients' response to treatment; 2) Complexity of resistance mechanisms: Oxaliplatin resistance mechanisms are very complex, involving multiple molecular pathways and biological processes, and current research is not in-depth enough, which limits the development of treatment strategies for resistance; 3) Cost and accessibility: Some personalized treatment technologies and drugs are expensive and may not be easily available in all regions and patients. This limits the popularity and scope of application of these treatment strategies; 4) The degree of personalization of treatment plans is not high: Although the concept of personalized treatment is widely recognized, in fact, in clinical practice, there is still a certain degree of standardized treatment. Differences in individual patients' genotypes, phenotypes, and environmental factors are not fully taken into account.

[0005] In summary, although personalized therapy has potential advantages in overcoming oxaliplatin or 5-FU-resistant CRC, there are still some technical shortcomings. Future research needs to focus on the screening of tumor molecular characteristics and the development of personalized treatment strategies for specific tumor targets. Summary of the invention

[0006] The purpose of the present invention is to overcome the shortcomings of the prior art and provide a use of a PCBP1 gene L100Q site mutation (L100 site T point mutation to A) in colorectal cancer drug resistance.

[0007] To achieve the above purpose, the technical solution adopted by the present invention is as follows:

[0008] In a first aspect, the present invention provides a use of a PCBP1 gene L100Q site mutation in the preparation of a biomarker for assessing the risk of drug resistance in colorectal cancer.

[0009] In a second aspect, the present invention provides a method for using the PCBP1 gene L100Q site mutation as a target in the preparation of a drug for treating and / or preventing drug resistance in colorectal cancer.

[0010] In a third aspect, the present invention provides a method for using the PCBP1 gene L100Q site mutation as a screening marker for drugs against colorectal cancer resistance.

[0011] In a fourth aspect, the present invention provides a method for using the PCBP1 gene L100Q site mutation as a target in the preparation of a diagnostic reagent for tumor resistance.

[0012] In a fifth aspect, the present invention provides a use of an inhibitor targeting the PCBP1 gene L100Q site mutation in the preparation of a drug for combating colorectal cancer resistance.

[0013] The present invention finds that RNA or DNA linker protein (Poly (rC)-binding protein 1, PCBP1) gene L100Q mutation (T point mutation at L100 site to A) can promote CRC tumor cell stemness and lead to CRC resistance to oxaliplatin and 5-FU, and can significantly promote CRC resistance to oxaliplatin or 5-FU at the cellular level compared with wild-type PCBP1, PCBP1 L100P (T point mutation at L100 site to C), and PCBP1 L100R (T point mutation at L100 site to G). The present invention provides a target (PCBP1 gene L100Q site mutation) that leads to CRC resistance to oxaliplatin and 5-FU, and can be used to guide personalized treatment of CRC patients.

[0014] As a preferred embodiment of the use described in the present invention, the drug resistance is resistance to chemotherapeutic drugs.

[0015] As a further preferred embodiment of the use described in the present invention, the chemotherapy drug is a platinum chemotherapy drug and / or 5-FU.

[0016] As a further preferred embodiment of the use described in the present invention, the platinum chemotherapy drug is cisplatin or oxaliplatin.

[0017] In a sixth aspect, the present invention provides a kit for assessing the risk of drug resistance in colorectal cancer, the kit comprising a reagent for detecting a mutation at the L100Q site of the PCBP1 gene.

[0018] As a preferred embodiment of the kit described in the present invention, the drug resistance is resistance to chemotherapeutic drugs.

[0019] Furthermore, the chemotherapy drug is a platinum chemotherapy drug and / or 5-FU.

[0020] Furthermore, the platinum chemotherapy drug is cisplatin or oxaliplatin.

[0021] Compared with the prior art, the present invention has the following beneficial effects:

[0022] The present invention first discovered that the PCBP1 gene L100Q site mutation can promote the stemness of CRC tumor cells and lead to CRC resistance to oxaliplatin and 5-FU. Compared with wild-type PCBP1, the PCBP1 gene L100Q site mutation can significantly promote the ability of CRC tumor sphere formation, while the PCBP1 gene L100P or L100R site mutation has no effect on the ability of CRC tumor sphere formation; the PCBP1 gene L100Q site mutation can significantly affect the expression of CRC tumor cell stemness-related proteins (EPCAM / OCT4 / SOX2 / NUMB); the PCBP1 gene L100Q site mutation can significantly increase the IC50 of oxaliplatin in the CRC tumor cell line (RKO), thereby promoting the resistance of the CRC tumor cell line to oxaliplatin; the PCBP1 gene L100Q site mutation can significantly increase the IC50 of 5-FU in the CRC tumor cell line (RKO), thereby promoting the resistance of the CRC tumor cell line to 5-FU. The PCBP1 gene L100Q mutation can significantly promote the stemness of CRC tumor cells and lead to CRC resistance to oxaliplatin and 5-FU. It can be used as a potential treatment site for CRC patients with oxaliplatin or 5-FU resistance. This potential target can be used to guide personalized treatment of CRC patients and has broad application prospects and important clinical value. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 :The PCBP1 gene L100Q mutation can significantly promote the tumor sphere formation ability of CRC tumor cells, while the PCBP1 gene L100P or L100R mutation has no effect on the tumor sphere formation ability of CRC tumor cells. The size and number of tumor spheres formed by different types of mutations at the PCBP1 gene L100 site in the CRC tumor cell line RKO were detected by in vitro sphere formation experiments. Among them, Figure 1 A is the morphology of tumor spheres formed by each group of cells under light microscopy. PCBP1 gene L100Q site mutation can significantly increase the volume of tumor spheres; Figure 1 B The number of tumor spheres formed in each group of cells was counted. PCBP1 gene L100Q site mutation can significantly increase the number of tumor spheres formed. (ns: P ≥ 0.05; ****: P < 0.0001)

[0024] Figure 2 :PCBP1 gene L100Q mutation can significantly affect the expression of stemness-related proteins in CRC.Western Blot was used to detect the expression of stemness-related proteins (EPCAM / OCT4 / SOX2 / NUMB) after different types of mutations at PCBP1 gene L100 in CRC tumor cell line RKO.

[0025] Figure 3:The PCBP1 gene L100Q mutation can significantly increase the IC50 of oxaliplatin in CRC tumor cell lines, thereby promoting the resistance of CRC tumor cell lines to oxaliplatin. CRC cell lines overexpressing the wild-type PCBP1 gene and CRC cell lines with PCBP1 gene L100 mutation were treated with oxaliplatin at a certain drug concentration gradient, and the IC50 of oxaliplatin in different groups was calculated to clarify their resistance to oxaliplatin. Among them, Figure 3 A shows that the PCBP1 gene L100Q site mutation promotes the cell activity of RKO under oxaliplatin treatment. The MTS method was used to detect the cell survival rate of RKO cell line after 48 hours of action of oxaliplatin at different concentrations (0.02μM, 1μM, 2μM, 5μM, 10μM, 20μM, 40μM, 80μM and 160μM). "----" means survival rate = 50%; Figure 3 B shows that the PCBP1 gene L100Q site mutation significantly increases the IC50 of oxaliplatin, thereby promoting the resistance level of RKO cell line to oxaliplatin.

[0026] Figure 4 :The PCBP1 gene L100Q mutation can significantly increase the IC50 of 5-FU in CRC tumor cell lines, thereby promoting the resistance of CRC tumor cell lines to 5-FU. RKO cell lines overexpressing wild-type PCBP1 gene and PCBP1 gene L100 mutation were treated with 5-FU at a certain drug concentration gradient, and the IC50 of 5-FU in different groups was calculated to clarify their resistance to 5-FU. Among them, Figure 4 A shows that the PCBP1 gene L100Q site mutation promotes the cell activity of RKO under 5-FU treatment. The MTS method was used to detect the cell survival rate of RKO cell line after 48 hours of action of 5-FU at different concentrations (0.02μM, 1μM, 2μM, 5μM, 10μM, 20μM, 40μM, 80μM and 160μM). "----" means survival rate = 50%; Figure 4 B shows that the PCBP1 gene L100Q site mutation significantly increases the IC50 of 5-FU, thereby promoting the resistance level of the RKO cell line to 5-FU. DETAILED DESCRIPTION

[0027] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.

[0028] The term "comprising" or "including" refers to including the elements, integers or steps described, but does not exclude any other elements, integers or steps. In the text, when the term "comprising" or "including" is used, unless otherwise specified, it also covers the situation consisting of the elements, integers or steps described.

[0029] "Point mutation": also known as single base substitution, refers to a mutation caused by a single base change, which is divided into two categories: conversion and transversion, where conversion is a substitution between purine and purine, or between pyrimidine and pyrimidine; transversion is a substitution between purine and pyrimidine. Point mutations can produce four different effects: synonymous mutations, missense mutations, nonsense mutations, and stop codon mutations. The effect caused by the mutation at the L100 site of the PCBP1 gene in the present invention is a missense mutation, which is a base substitution mutation that can cause a change in the amino acid sequence of the polypeptide product or a change in the functional RNA base sequence.

[0030] "Tumor sphere formation ability": refers to the ability of tumor cells (here specifically the CRC tumor cell line RKO) to form tumor spheres when cultured in vitro in a medium containing EGF and bFGF. It is the gold standard for measuring the stemness of tumor cells.

[0031] "Tumor cell stemness" refers to the ability of tumor cells to self-renew and differentiate similar to stem cells. This stemness allows tumor cells to proliferate indefinitely, form tumors, and be resistant to conventional treatments. It is regulated by multiple signaling pathways, including Notch, Wnt, Hedgehog, etc. Abnormal activation or inhibition of these signaling pathways can lead to an increase or decrease in tumor cell stemness. Tumor cell stemness is considered to be one of the important causes of tumor recurrence, metastasis and drug resistance.

[0032] "IC50": also known as half inhibitory concentration, is a commonly used indicator in the fields of biology and pharmacology to measure the level of inhibition or activity of a compound or drug on a biological system. The IC50 value indicates the concentration at which a compound or drug inhibits a biological process or activity by 50% under specific conditions. In the present invention, the higher the IC50, the greater the resistance of the tumor cell line to oxaliplatin or 5-FU, and the stronger the drug resistance.

[0033] To better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments. It should be understood by those skilled in the art that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.

[0034] Unless otherwise specified, the experimental methods used in the examples are all conventional methods; the materials and reagents used, unless otherwise specified, can be obtained from commercial sources. The accession number of the nucleotide sequence of PCBP1 on NCBI is NG_029956.1.

[0035] Embodiment 1:

[0036] CRC cell lines stably overexpressing wild-type PCBP1 and mutant PCBP1 (L100P / L100Q / L100R) were constructed.

[0037] (1) It was confirmed that the wild-type CRC cell line RKO (purchased from ATCC, USA) had no mutation at the L100 site of the PCBP1 gene: the culture medium of the RKO adherent cells in good growth state was discarded, the cells were washed twice with PBS and the supernatant was removed; the genomic DNA of the RKO cell line was extracted according to the product instructions of the Genomic DNA Purification Kit (EZ Bioscience, Cat. No.: B0007), and PCR amplification was performed with the corresponding primers and then sequencing was performed to confirm that the PCBP1 gene L100 site of the RKO cell line had no mutation.

[0038] (2) According to the instructions of ViaFectTM Transfection reagent, human PCBP1 sgRNA plasmid (the vector uses pLenti-U6-hPCBP1 sgRNA-EFS-NS-SpCas9-2A-Puro, lentiviral backbone, puromycin resistance, purchased from Shanghai Lianfeng / Guangzhou Youming Biotechnology Co., Ltd.) was transferred into the RKO cell line. After 36 hours of transfection, the cells were collected and re-plated in 96-well plates for culture according to the gradient dilution method; after the cells were statically cultured for 7-10 days, the cell clone formation was observed under a microscope. When a single cell clone was observed in the well, the well was marked; after the clone grew to an appropriate size, two copies of the 96-well plate single clone were backed up, one copy was continued to be cultured, and the other copy was used to extract genomic DNA for testing, until the PCBP1 knockout RKO cell line was finally screened.

[0039] (3) Obtain plasmids (pLenti-U6-EFS-NS-SpCas9-2A-Blast, lentiviral backbone, with 3Flag tag, Blast resistance) that stably overexpress wild-type PCBP1 (WT-OE) and mutant PCBP1 (L100P / L100Q / L100R): purchased from Shanghai Lianfeng Biotechnology Co., Ltd. and Guangzhou Youming Biotechnology Co., Ltd.

[0040] (4) Virus liquid packaging: 293T cells in good condition were inoculated into a 10 cm cell culture dish, and virus packaging could be performed when the cell density reached 80%; virus packaging plasmid and target plasmid (plasmids stably overexpressing wild-type PCBP1 (WT-OE) and mutant PCBP1 (L100P / L100Q / L100R)) were prepared in proportion, and the system was: Opti-MEM 200 μL + psPAX2 6 μg + pMD2.G 2 μg + target plasmid 8 μg + PEI (0.5 mg / mL) 100 μL; after adding PEI reagent, vortex thoroughly, let stand at room temperature for 15 minutes, and then add dropwise to the 293T cell culture medium; after 8 hours of cell transfection, fresh culture medium was replaced for continued culture, and 1:500 sodium butyrate; collect the cell supernatant containing the virus after 48 hours of culture, centrifuge the virus supernatant at 3000rpm for 5 minutes, discard the cell debris at the bottom of the tube and collect the supernatant; filter the supernatant with a 0.45μm pore filter to obtain the virus solution, divide it into portions and freeze it at -80℃ to avoid repeated freezing and thawing.

[0041] (5) Lentivirus infection of eukaryotic cells: PCBP1-knockout RKO cell lines were plated in 6-well plates in advance. The culture medium was discarded on the next day, and 1 mL of fresh culture medium and 1 mL of the filtered virus solution were added to each well. At the same time, 2 μL of 2 mg / mL Polybrene was added. After mixing, the cells were placed in a cell culture incubator for culture. After 10 hours of infection, the culture medium was discarded and 2 mL of fresh complete culture medium was added for continued culture. After 24 hours, 10 μm Blast antibiotic selection was started.

[0042] (5) Finally, Western blotting was used to verify the CRC cell line RKO that stably overexpressed wild-type PCBP1 (WT-OE) and mutant PCBP1 (L100P / L100Q / L100R).

[0043] Embodiment 2:

[0044] The size and number of tumor spheres formed by different types of mutations at the L100 site of the PCBP1 gene in the CRC cell line RKO were detected by an in vitro sphere formation experiment.

[0045] (1) Prepare tumor cell sphere formation medium: add 20 μL / mL B27, 20 ng / mL EGF, 20 ng / mL bFGF, 10 μg / mL heparin and 10 μL / mL P / S to DMEM / F12 medium.

[0046] (2) The RKO cell lines with good growth and stable overexpression of wild-type PCBP1 (WT-OE) and mutant PCBP1 (L100P / L100Q / L100R) obtained in Example 1 were digested and centrifuged, the serum-containing medium was removed, and the cells were washed twice with PBS, and then resuspended in the above-mentioned spheroidization medium to form a single cell suspension for cell counting, and plated in a 96-well cell culture plate. Each group of cells was plated in 3 replicates, 500 cells / well, and 100ul of culture medium was added to each well.

[0047] (3) At 37°C, 5% CO 2 The cells were cultured under the same conditions, and the spheroid formation medium was gently added every 2-3 days. The morphology and growth of the cell spheroids were observed under a microscope.

[0048] (4) On the sixth day of culture, the morphology of the tumor spheres in each treatment group was observed under a microscope, and the number of cell spheres with a diameter greater than 50 μm in each well of each treatment group was counted.

[0049] Results Figure 1 Compared with the WT-OE group, the PCBP1 gene L100Q site mutation can significantly promote the CRC tumor sphere formation ability, while the PCBP1 gene L100P or L100R site mutation has no effect on the CRC tumor sphere formation ability.

[0050] Embodiment 3:

[0051] The Western Blot method was used to detect the expression of stemness-related proteins (EPCAM / OCT4 / SOX2 / NUMB) after different types of mutations at the L100 site of the PCBP1 gene in the CRC tumor cell line RKO.

[0052] (1) Protein sample extraction of adherent cells: Culture cells in a culture dish with a diameter of 10 cm, collect cell proteins when the cells grow to a density of 80%; wash the cells three times with pre-cooled PBS; prepare RIPA Lysis buffer (500 ml): 400 mM NaCl 11.7 g, 25 mM HEPES 3 g, 0.2 mM EDTA, NA2EDTA2H2O 0.037 g, 1.5 mM MgCl20.007 g, 1% NP40; add protease inhibitors to RIPA Lysis buffer at a ratio of 1:100; place the culture dish on ice, add about 500 μL of pre-cooled RIPA Lysis buffer containing protease inhibitors, and shake the culture dish to allow RIPA Lysis to absorb. The buffer was evenly distributed in the culture dish to fully lyse the cells, and the cells were scraped off with a cell scraper washed with pure water and transferred to a new pre-cooled EP tube and placed on ice for 20 minutes; centrifuged at 13000 rpm at 4°C for 15 minutes to precipitate the cell fragments at the bottom of the tube; the supernatant was collected and transferred to a new pre-cooled EP tube; mixed with 5×SDS loading buffer and RIPALysis buffer and boiled in a 95°C metal bath for 10 minutes.

[0053] (2) The protein samples after the above treatment were subjected to protein electrophoresis, membrane transfer, antibody incubation (EPCAM: abcam, ab32392; OCT4: abcam, ab181557; SOX2: Proteintech, 10006239; NUMB: abcam, ab14140) and development in sequence to finally obtain the required images.

[0054] EPCAM is a surface marker of tumor stem cells and a type I transmembrane polypeptide that is associated with cell adhesion, proliferation, differentiation, and migration. OCT4 is an embryonic stem cell transcription factor. Its expression in tumors indicates the presence of stem cell-like tumor cells, which can cause early metastasis, infiltration, resistance to radiotherapy and chemotherapy, and recurrence after treatment of malignant tumors. SOX2 is a key transcription factor for stem cells. In addition to maintaining the potential for stem cell self-renewal and multidirectional differentiation, its high expression in tumor cells can promote tumor proliferation, differentiation, invasion, metastasis, and drug resistance. NUMB is more considered to be a tumor suppressor factor. Its tumor suppressor mechanism is not only related to processes such as cell polarity, cell division direction, and epithelial-mesenchymal transition, but is also closely related to important pathways such as Notch, p53, and Hh. Results are shown in Figure 2 The PCBP1 gene L100Q site mutation can significantly affect the expression of CRC stemness-related proteins.

[0055] Embodiment 4:

[0056] CRC cell lines overexpressing the wild-type PCBP1 gene and CRC cell lines with PCBP1 gene L100 mutation were treated with oxaliplatin at a certain drug concentration gradient, and the IC50 of oxaliplatin in different groups was calculated to clarify their tolerance to oxaliplatin.

[0057] (1) RKO cell lines in the logarithmic growth phase overexpressing wild-type PCBP1 and PCBP1 gene L100 mutant groups were digested, resuspended, counted, and plated in a 96-well plate at 2000 cells / well;

[0058] (2) Each group was treated with the following oxaliplatin concentration gradient: 0 μM, 0.02 μM, 1 μM, 2 μM, 5 μM, 10 μM, 20 μM, 40 μM, 80 μM, and 160 μM;

[0059] (3) After 48 hours, the cell viability was detected using the MTS method: the corresponding volume of MTS detection solution was prepared as required, and serum-free culture medium was added at a ratio of detection solution: culture medium = 1:5, and the culture medium was incubated at 37°C and 5% CO 2 Incubate for 2 hours; read the data at the absorption peak of 490nm based on the absorbance spectrum of the formazan product produced after MTS reduction, and subtract the data read at 630nm to subtract the noise value caused by cell debris, etc., and other non-specific absorbance values; calculate the cell survival rate based on the absorbance value A, cell survival rate = (experimental group A / control group) × 100%. Calculate the IC50 value and draw a dose-response curve.

[0060] Results Figure 3 Compared with the WT-OE group, the PCBP1 gene L100Q site mutation in CRC tumor cell lines can significantly increase the IC50 of oxaliplatin, thereby promoting the resistance of CRC tumor cell lines to oxaliplatin.

[0061] Embodiment 5:

[0062] CRC cell lines overexpressing the wild-type PCBP1 gene and CRC cell lines with PCBP1 gene L100 mutation were treated with 5-FU at a certain drug concentration gradient, and the 5-FU IC50 of different groups was calculated to clarify their tolerance to 5-FU.

[0063] (1) RKO cell lines in the logarithmic growth phase overexpressing wild-type PCBP1 and PCBP1 gene L100 mutant groups were digested, resuspended, counted, and plated in a 96-well plate at 2000 cells / well;

[0064] (2) Each group was treated with the following 5-FU concentration gradient: 0 μM, 0.02 μM, 1 μM, 2 μM, 5 μM, 10 μM, 20 μM, 40 μM, 80 μM, and 160 μM;

[0065] (3) After 48 hours, the cell survival rate was detected using the MTS method: the corresponding volume of MTS detection solution was prepared as needed, and serum-free culture medium was added at a ratio of detection solution: culture medium = 1:5, and incubated at 37°C, 5% CO2 for 2 hours; according to the absorbance spectrum of the formazan product produced after MTS reduction, the data was read at the absorption peak of 490nm, and the data read at 630nm was subtracted to subtract the noise value caused by cell debris, etc., and other non-specific absorbance values; the cell survival rate was calculated based on the absorbance value A, and the cell survival rate = (experimental group A / control group) × 100%. The IC50 value was calculated and a dose-response curve was drawn.

[0066] Results Figure 4 Compared with the WT-OE group, the PCBP1 gene L100Q site mutation in CRC tumor cell lines can significantly increase the IC50 of 5-FU, thereby promoting the resistance of CRC tumor cell lines to 5-FU.

[0067] In summary, the present invention found that compared with wild-type PCBP1, PCBP1 gene L100Q site mutation can significantly promote CRC tumor sphere formation ability and affect the expression of stemness-related proteins; by treating the corresponding cell lines with in vitro drug gradient concentrations, it was confirmed that PCBP1 gene L100Q site mutation significantly promotes CRC resistance to oxaliplatin and 5-FU. This potential target can be used to guide personalized treatment of CRC patients, such as evaluating and predicting the therapeutic effect of chemotherapy for patients, and tailoring personalized treatment plans. At the same time, this target is expected to become a potential treatment site for CRC oxaliplatin or 5-FU resistant patients, which has important clinical value.

[0068] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.

Claims

1. Use of the PCBP1 gene L100Q site mutation in the preparation of a biomarker for assessing the risk of drug resistance in colorectal cancer.

2. Use of the PCBP1 gene L100Q site mutation as a target in the preparation of drugs for treating and / or preventing colorectal cancer resistance.

3. Use of PCBP1 gene L100Q site mutation as a screening marker for drugs that are resistant to colorectal cancer.

4. Use of PCBP1 gene L100Q site mutation as a target in the preparation of diagnostic reagents for tumor resistance.

5. Use of inhibitors targeting the PCBP1 gene L100Q site mutation in the preparation of drugs to combat colorectal cancer resistance.

6. The use according to any one of claims 1 to 5, characterized in that: The drug resistance is resistance to chemotherapy drugs.

7. The use according to claim 6, characterized in that The chemotherapy drugs are platinum chemotherapy drugs and / or 5-FU.

8. The use according to claim 7, characterized in that The platinum chemotherapy drug is cisplatin or oxaliplatin.

9. A kit for assessing the risk of drug resistance in colorectal cancer, characterized in that: The kit comprises a reagent for detecting the L100Q site mutation of the PCBP1 gene.

10. The kit according to claim 9, characterized in that The drug resistance is resistance to chemotherapy drugs.

Citation Information

Patent Citations

  • Application of METTL2 gene in preparation of kit for detecting treatment sensitivity of colorectal cancer fluorouracil drugs

    CN111518909A